The inhibition of CD11b+ cell recruitment through different approaches (i.e., CXCR-4 or SDF-1 inhibition) impairs tumor regrowth after single dose or fractionated RT in rat glioblastoma model and in murine prostate cancer model (Chen et al., 2013; Liu et al., 2014). Here, CXCR4 is linked to neoplasm.